Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.485 USD | -1.25% | -3.84% | -0.24% |
Financials (USD)
Sales 2024 * | 239K | Sales 2025 * | 8.8M | Capitalization | 157M |
---|---|---|---|---|---|
Net income 2024 * | -119M | Net income 2025 * | -147M | EV / Sales 2024 * | 36 x |
Net cash position 2024 * | 149M | Net cash position 2025 * | 136M | EV / Sales 2025 * | 2.48 x |
P/E ratio 2024 * |
-1.21
x | P/E ratio 2025 * |
-1.33
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.21% |
Latest transcript on Adverum Biotechnologies, Inc.
1 day | +0.80% | ||
1 week | -5.49% | ||
Current month | -4.29% | ||
1 month | -27.33% | ||
3 months | -59.68% | ||
6 months | -14.35% | ||
Current year | +0.69% |
Managers | Title | Age | Since |
---|---|---|---|
Laurent Fischer
CEO | Chief Executive Officer | 60 | 20-06-14 |
Linda Rubinstein
DFI | Director of Finance/CFO | 58 | 22-12-11 |
Bill Tan
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Whitcup
BRD | Director/Board Member | 64 | 20-04-15 |
Clarence Machado
CHM | Chairman | 60 | 17-03-13 |
Laurent Fischer
CEO | Chief Executive Officer | 60 | 20-06-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 7.51 | -0.92% | 9 870 |
24-06-05 | 7.58 | +0.80% | 104,178 |
24-06-04 | 7.52 | -2.97% | 110,936 |
24-06-03 | 7.75 | -2.15% | 170,012 |
24-05-31 | 7.92 | +1.41% | 295,956 |
Delayed Quote Nasdaq, June 05, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.69% | 157M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+2.18% | 22.67B | |
-10.09% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- ADVM Stock